B38.1 Chronic pulmonary coccidioidomycosis

Name of the Condition

• Chronic pulmonary coccidioidomycosis

Summary

Chronic pulmonary coccidioidomycosis is a fungal infection of the lungs caused by Coccidioides species. It represents a persistent form of coccidioidomycosis, characterized by ongoing or recurrent pulmonary symptoms lasting beyond the acute phase. The condition may involve chronic inflammation, fibrosis, or cavitation in the lungs and can range from mild, stable disease to progressive respiratory impairment, particularly in immunocompromised individuals.

Causes

The infection results from inhaling airborne spores of Coccidioides fungi, which are endemic to arid regions such as the southwestern United States, Mexico, and parts of Central and South America. These spores are released from soil and can become airborne during activities that disturb the ground, including construction, farming, or windstorms. Inhalation of the spores leads to infection, with the lungs being the primary site of involvement. Chronic disease may develop if the initial infection is not fully resolved or if the immune system fails to clear the organism.

Risk Factors

• Residence or travel to endemic regions, especially during dry, dusty seasons.
• Occupational exposure to soil (e.g., farmers, construction workers, archaeologists).
• Immunocompromised states, including HIV/AIDS, organ transplantation, or prolonged corticosteroid use.
• Advanced age.
• Pre-existing lung disease (e.g., chronic obstructive pulmonary disease).

Symptoms

• Persistent cough, often with sputum production.
• Chest pain or discomfort.
• Shortness of breath or wheezing.
• Fatigue and malaise.
• Low-grade fever or night sweats.
• Weight loss.
• Hemoptysis (coughing up blood) in severe cases.
• Chronic respiratory symptoms that may mimic tuberculosis or other lung diseases.

Diagnosis

Diagnosis involves clinical evaluation, imaging (e.g., chest X-ray or CT scan) to assess lung involvement, and laboratory testing. Imaging may reveal chronic changes such as cavities, nodules, or fibrosis. Laboratory confirmation typically includes serologic tests (e.g., coccidioidomycin antibody detection) or fungal culture of respiratory specimens. Biopsy may be performed in cases of atypical presentation or to rule out malignancy. Chronic disease is distinguished by persistent symptoms and radiographic findings beyond the acute phase.

Treatment Options

Treatment depends on the severity of symptoms and immune status. Mild cases may be managed with observation, while moderate to severe disease often requires antifungal therapy (e.g., fluconazole, itraconazole) for extended periods (months to years). Surgery may be necessary for complications like large cavities, persistent hemoptysis, or fungal balls. Immunocompromised patients typically require longer or more aggressive treatment. Regular monitoring of lung function and imaging is essential to assess response.

Prognosis and Follow-Up

Prognosis varies; many patients achieve stable disease with treatment, but some may experience chronic respiratory impairment or relapse. Follow-up includes regular clinical assessments, imaging, and serologic monitoring to detect recurrence or progression. Immunocompromised individuals require closer surveillance due to higher risk of severe disease. Long-term outcomes depend on the extent of lung damage and adherence to therapy.

Complications

• Progressive lung fibrosis or cavitation.
• Respiratory failure.
• Fungal dissemination to other organs (e.g., bones, skin, central nervous system).
• Hemoptysis from cavitary lesions.
• Secondary bacterial infections in damaged lung tissue.
• Chronic respiratory symptoms impacting quality of life.

Lifestyle & Prevention

• Avoid exposure to dust in endemic areas, especially during dry seasons or activities like construction.
• Use respiratory protection (e.g., masks) in high-risk environments.
• Maintain overall health to support immune function.
• Follow prescribed treatment regimens consistently.
• Seek prompt medical care for persistent respiratory symptoms after potential exposure.

When to Seek Professional Help

Consult a healthcare provider if you experience persistent cough, chest pain, shortness of breath, or unexplained weight loss, especially after travel to or residence in endemic regions. Seek immediate care for severe symptoms like hemoptysis, high fever, or signs of respiratory distress.

Tips for Medical Coders

Document the chronic nature of the pulmonary infection, including clinical details (e.g., duration, radiographic findings, treatment response) to support the B38.1 code. Ensure documentation differentiates chronic disease from acute or unspecified pulmonary coccidioidomycosis. Include any relevant risk factors or complications that may impact coding or clinical management.